1. visit our website:
www.flemingeurope.com
OUR SPEAKER PANELOur features
2015 AT A GLANCE
Thought-provoking agenda
Valuable insight from 15+
experts representing top
pharma and biotech companies
Inspiring case studies
Interactive group sessions
Building an action plan
activities
Project
& Portfolio
Management
in the Pharmaceutical Industry
28 – 29 October 2015, Vienna, Austria
11th
• Program & lifecycle management
• Project Prioritisation tools
• Initiatives to improve Project Delivery Capabilities
• Handling complex projects
• Portfolio optimisation
• Resource management
• Crossing cultural barriers: unknown unknowns
• R&D productivity measures
• PPM in licensing strategies
• Co-development programs and partnerships
and more...
Media Partners:
Ulrike Grimm, Vifor Pharma
Vice President Head Global Project and R&D
Alliance Management
Hannes Loferer, Onconova Europe
VP Project Planning & Portfolio Management
Jörg Meil, Boehringer-Ingelheim Animal
Health
Head Global Pharmaceuticals R&D and
International Project Management
Peter Luke, Novo Nordisk
Director of Global Project Office
Rainer Mussmann, Novartis
Associate Director, Project Management
Office
Yvette Miata Petersen, Novartis
Associate Director, Project Management
Office
Sakir Mutevelic, Baxter BioScience
Director Global Program & Portfolio
Management
Frank Rebers, Genmab
Associate Director Project Management
Office
Verena Lutz, Roche
Global Project Manager, Portfolio & Strategy
Marie Bernasconi
Pierre Fabre Pharmaceuticals
Head of R&D Portfolio and Program Strategy
Chiara Mazzoli, Chiesi
Project Manager
Katrine Husum, LEO PHarma
Senior Project Leader
Jacques Marcel, Sanofi Pasteur - TBC
Head of Project Management Office,
Commercial Operations

2. OUR ADVISORY COMMITTEE
‘Very educational and pleasant three days. The workshop was
great, as well as the interactions and discussions. Nicely organised!’
Project Manager, LEK Pharmaceuticals
“Good to see that small and big, traditional and innovative
industries face the same challenges with the same tools”
Head of Project Management and Processes, Chiesi
Farmaceutici
“Excellent event, thanks!”
Global Project Manager, Zentiva
“Your event was a great opportunity to network and share
experience. It was on a very good expert level.”
Director Competitive R&D Intelligence
Boehringer Ingelheim
“Very good speakers with bright ideas. The event was very
enlightening and provided a great opportunity to meet the Best in
the industry.”
Head of International Business Development
Acino Pharma
11th
Project & Portfolio Management
in the Pharmaceutical Industry
CxOs, SVPs, VPs, Global heads, Heads, Directors, Senior Managers,
Managers, Team Leaders, Researchers, Scientists of Pharma/
Biotech companies responsible for:
Portfolio Management, Project Management, Lifecycle
Management, Pharmaceutical Development, R&D, Portfolio
Strategy, Strategic Planning & Decision, Strategy & Portfolio
Analysis, Portfolio Selection, Decision Analysis, Business
Development, Alliances...
A large number of companies have
registered for our PPM events, is your
company among them?
Whay do they say about it
Abbott, Acino Pharma, Actelion, AHP Manufacturing - Wyeth
Medica Ireland, Algeta, ALK-Abello, Almirall, Amgen, Apogenix,
Arterium Pharmaceutical Corporation, Astellas Pharma Europe,
AstraZeneca,AxelliaPharmaceuticals,BaxterInternational,Bayer
Healthcare, Bayer Schering Pharma AG, Boehringer Ingelheim,
Catenion, Celgene, CEVA Sante Animale, Chiesi Farmaceutici,
CSL Behring, DebioPharm, Dompe Pha.R.Ma, Elli Lilly, Enrich
Consulting, F.Hoffmann-La Roche, Ferring International Center,
Fertin Pharma, Fresenius Medical Care, Galapagos, Galderma,
Genentech, Genmab, Genzyme, GlaxoSmithKline, Glenmark
Pharmaceuticals, Grunenthal GmbH, Hovione FarmaCiencia,
IMS Health, Institute de Recherche Pierre Fabre, Ipsen, Kinapse,
LEO Pharma, Lundbeck, Medimmune, Merck KGaA, Merck
Serono, Merck Sharp & Dohme, Merial, Merz Pharmaceuticals
GmbH, Novartis, Novo Nordisk, Nycomed, Orion Pharma,
Pfizer, Pharmaxis, Ratiopharm, Roche, Sandoz, Sanofi,
Sanofi Pasteur, Santen, Sartorius AG, Sigma-Tau Spa, Solvay
Pharmaceuticals, Stada, Swedish Orphan Biovitrum, Teva
Pharmaceuticals, UCB, Vertex Pharmaceuticals, Vifor Pharma,
Wockhardt, Xellia Pharmaceuticals, Zambon Spa...
Who will you meet
Jörg Meil
Boehringer-Ingelheim Animal Health
Head Global Pharmaceuticals R&D and
International Project Management
Hannes Loferer
Onconova Europe GmbH
VP Project Planning and Portfolio Management
Varada Bapat
Wockhardt
Associate Vice President Project Management

3. CONFERENCE FEATURES
11th
Project & Portfolio Management
in the Pharmaceutical Industry
Meet & Greet Networking Session
To boost networking and interactivity right from the beginning, we will start the conference
with a small exercise. The attendees will have 10 minutes to exchange as many business cards
as possible.
Building An Action Plan
Participants will be asked to “Build An Action Plan”, a step by step guide, throughout the two
days of the conference. This session is an essential part of the whole conference programme that
has been designed to give you take-aways to act upon, therefore we encourage participants to
engage in conversations, exchange observations and share knowledge and experience.
• After each group of presentations, participants will be given the time to further discuss in
groups concerns in that particular area and solutions that could enhance their roles as project
and portfolio managers and that could be implemented in their organisations.
• There will be four group activities where the discussion should be focused on creating a step
by step plan that could be used by participants back in their offices.
• Each group leader will present to the whole audience their group solution with a step by step
action plan.
Breakout Sessions
Breakout sessions are interactive, guided discussions hosted by a facilitator to discuss some of
the key issues presented earlier in the day’s sessions. Participants will join a table of interest and
become an active part of the discussion at hand. To get the most out of this interactive session
and format please come prepared to share examples from your work, share some ideas with
your peers, be a part of group discussions, and, most importantly, participate in active idea
sharing.
The Talk
After an introduction to the topic given by one of our speakers, participants will have the
opportunity to share their knowledge and experience. We will have 5 chairs arranged in an
inner circle and will start with a ‘closed circle‘ with speakers. The audience outside the circle
will listen to beginning of the discussion and when a member of the circles leaves and a chair
is left empty, any member of the audience can, at any time, occupy the empty chair and join
the circle and the discussion. The discussion continues allowing several people to participate in
the conversation.
Spotlight Session
Our interactive spotlight session address the differences and similarities in project and portfolio
management in specific therapeutic areas. Panellists share their own thoughts and experience
and react to the audience’s questions.
Networking Cocktail Reception
Our cocktail party will take place after the first day of the conference and it is aimed to promote
networking between participants and can be an opportune time for helping your career.

4. 28 October 2015
8:30 Registration coffee
9:00 Welcoming note from Fleming Europe
9:05 Opening remarks from the Chair
9:15 “Meet & Greet Networking Session”
9:20 Translating Companies Strategies into Projects
• Does your company have a strategy and do people know and
understand it?
• Does project portfolio strategy have a direct link to the
organisation strategy?
• How to take a holistic approach
Ulrike Grimm, Vifor Pharma
Vice President Head Global Project and R&D Alliance Management
10:00 Handling Complex Projects/Programs in Complex
Matrix Organisational Structure
• Main focus on Project Team and Project Sub-teams Structure
• Reflecting on experience in developing competence framework
for Project/Program Management success across the
organisation
Sakir Mutevelic, Baxter BioScience
Director Global Program & Portfolio Management
10:30 Project Prioritization - Getting Project Decisions Right
to Achieve Success
• What are the priorities in a changing environment with limited
resources?
• How do we ensure our project portfolio best supports the
company strategy?
• Selecting the best set of projects to achieve the organisation‘s
goals
• Determining what portfolio-level metrics could be used to
characterise what the executive team would see as a ‚good‘
portfolio
Jörg Meil, Boehringer-Ingelheim Animal Health
Head Global Pharmaceuticals R&D and International Project
Management
11:00 Morning coffee & networking
11:30 Project Optimization –The Path from Discovery to Early
Development
• How can the definition of Key Scientific Questions drive
optimized Project development
• Risk Management Plans: A useful tool in optimization
• Implementation of “Optimized” decisions: Team or
Management Responsibility?Dealing with emotional reactions
to optimization
Yvette Miata Petersen, Novartis
Associate Director, Project Management Office
12:00 How to Ensure that the Necessary Resources Are
Available
• How to best align the delivery of projects considering the
constraints of internal resources and overall R&D budget
• Re-thinking the deployment of resources internally in light
of the rising numbers of projects across the industry at every
development phase
• Establishing an integrated R&D operations environment to align
project, resource, finance and portfolio management
12:30 GROUP ACTIVITY – Building an Action Plan Step 1
• How do you organise roles and responsibilities to optimise
performance?
• How do you overcome cross-cultural barriers?
• How to break-up silos in an organisation
• What criteria should be used when prioritising projects? When
terminating a project? What are the procedures / strategies to
best allocate those resources to a new project? Are they aligned
with company‘s strategy?
12:50 Lunch
14:00 Aligning Portfolio with the Organisation’s Goals and
Objectives – From Past to Future.
• Portfolio analysis and tracking
• Setting goals and creating pipeline strategy
• Long term forecasting of resources and budgets
Frank Rebers, Genmab
Associate Director Project Management Office
14:30 Delivering Portfolio Optimisation
• Predictive modelling and simulation & optimisation capabilities
• Data sources and criteria selection of new pipeline candidates
• Uncertainties of the elements - Communicating uncertainty in
your portfolio
15:00 Building a Portfolio for the Future – Looking into
Market Access and Reimbursement
• Incorporating pharma-economics in early stages of product
development to understand the reimbursement landscape
• How can payers influence R&D choices?
• How can pharmaceutical companies launch new products and
satisfy payers with different standards and needs?
• How does the increased Payer focus match with being Patient
Centric?
Katrine Husum, LEO PHarma
Senior Project Leader
15:30 Afternoon tea & networking
16:00 BREAKOUT SESSIONS
Sharing, Hedging and Mitigating
Risk
• Risk valuation as a powerful
tool in project and portfolio
management
• How do risk assessment results
drive portfolio decision?
Dynamic Project and Portfolio
Management
What is the role of regulatory
affairs and HTAs in defining
key project parameters in drug
development?
Which challenges do the EMA and
national HTAs and their different
requirements represent? And how
can this be managed from today‘s
perspective?
Does this impact the valuation of
drug development projects (e.g.
also in the context of licensing
negotiations?
Big Data – How can the portfolio
benefit from big data?
• Can Big Data analytics enable
faster and better decision
making in R&D from new
insights, leading to improved
R&D productivity?
16:30 GROUP ACTIVITY – Building an Action Plan Step 2
• What are the methods to identify new pipeline candidates?
• How can you best monitor that the portfolio is at all times
aligned with your company‘s goals?
• How does the performance of project portfolios relies on
uncertainties?
• How should expectations about portfolio performance be
reviewed according to those uncertainties?
• How can you best apply the payers‘ concern to your portfolio
selection?
16:50 The Talk – The Project & Portfolio Management
Function
• Is Project & Portfolio Management a discipline on its own?
• Is It a Marketing function? Or a Commercial one? should PPM
be integrated in R&D? Can it be an independent function?
• What are the pros and cons of each of these options?
• What would be the ideal reporting system?
Marie Bernasconi, Pierre Fabre Pharmaceuticals
Head of R&D Portfolio and Program Strategy
17:20 Closing remarks from the Chair
Speakers and delegates are cordially invited to attend a
Networking Cocktail Reception
MAIN FORUM
DAY
tel.: + 421 257 272 290, fax: + 421 255 644 490
killian.mabena@flemingeurope.com, www.flemingeurope.com

5. 29 October 2015
MAIN FORUM
DAY
9:00 Welcoming note from the Chair
9:10 SPOTLIGHT SESSION: Project & Portfolio Management
in Specific Therapeutic Areas
Each of the panel speakers will deliver a 15-minute
presentation, a case study on the different project and
portfolio management strategies and approaches used for
specific therapeutic areas (oncology, diabetes, orphan drugs,
neurology, immunology, etc.) The presentations will be
followed by a discussion with the panel moderator and the
audience.
Managing an Early clinical Portfolio in the
Autoimmunity and Immunology area
Rainer Mussmann, Novartis
Associate Director, Project Management Office
Pathways for of new oncology drugs – with emphasis
on early approval pathways (USA vs Europe)
• Two case studies from a project management perspective
• Biologic with immune based mechanism in lung cancer
• Small molecule signal pathway inhibitor in hematological
cancer
• Retrospective summary of key decisions on the
development path, their risks and impact.
• Lessons learned summary.
Hannes Loferer, Onconova Europe
VP Project Planning & Portfolio Management
10:30 Quantity Measures for R&D Performance
• Capacity Planning and Performance Tracking – how to
integrate progressive KPIs systems to evaluate projects
• How to leverage resource planning and pipeline operations
to deliver on strategic R&D goals
• How to monitor the expenses in R&D and control the
project end to end
11:00 Morning coffee & networking
11:30 Integrating Tools in R&D Portfolio Management
• How tools ensure the most strategic value out of companies
R&D investment
• Connecting and harmonising functional areas within the
organisation
• Real-time data available across the organisation to support
decision making
12:00 GROUP ACTIVITY: Building an Action Plan Step 3
• What methods and techniques do you use to measure R&D
productivity?
• What are the do‘s and don‘ts?
• What tools do you use to support R&D performance?
12:20 Lunch
13:20 Collaborative Project Management: Empowering
Project Team Members and Overcoming Barriers of
Time and Space
• What are the benefits of collaborative project management?
• How can collaborative project management improve
efficiencies, enhance competitive advantage, and result in
more successful projects?
Verena Lutz, Roche
Global Project Manager, Portfolio & Strategy
13:50 Project Team Members: Collaboration and
Communication
• Team members: Role and accountabilities
• Why should team members be empowered?
• What tools can the project manager use to increase
collaboration and communication within the team?
• New challenges: multicultural and virtual teams
• What is a virtual team? How to manage the obstacles of
virtual teams?
Chiara Mazzoli, Chiesi
Project Manager
14:20 Developing New Models of Partnership: Innovation
through Internal and External Collaboration
• Identifying the drivers, benefits and advantages of
partnerships
• How does the partnership affect the portfolio?
• Translational research support
• Designing the right global portfolio of R&D partners and
service providers and avoid complexity and inefficiency
• How to set up and effectively utilise a network of partner
service providers to dramatically improve R&D performance
14:50 GROUP ACTIVITY: Building an Action Plan Step 4
• What are the most efficient internal and external
collaboration models?
• How do you manage the complexity of collaboration with
academia and solution providers?
• What are the challenges? How do you overcome those?
15:10 WRAP UP Session
Attendees will have the opportunity to share their findings
and take-aways after two days of interesting and valuable
presentations and will be given the opportunity to ask extra
questions to speakers.
15:20 Closing remarks from the Chair
15:30 Farewell Coffee and Networking
tel.: + 421 257 272 290, fax: + 421 255 644 490
killian.mabena@flemingeurope.com, www.flemingeurope.com

6. 11th
Annual Project & Portfolio Management in the Pharmaceutical Industry
28 – 29 October 2015, Vienna, Austria
Terms and Conditions:
These terms and conditions represent an integral part of this contract between Event Production, s.r.o. and a client, which is specified
above, and who by signing this registration form fully and without any doubt or uncertainty accepts all following terms and conditions:
1. Payment terms. Event Production, s.r.o. (hereinafter as “EP”) requires the full payment of the invoiced amount within 5 working days
from the issue date of the invoice. EP reserves the right to refuse entry to any client who does not pay the invoice in full and on time.
The registration fee includes: conference documentation, admission to all conference sessions, lunches and refreshments, admission to
networking social breaks during the event. The registration fee does not include: travel, hotel accommodation, transfers or insurance.
2. Hotel accommodation. Overnight accommodation is not included in the registration fee. A reduced rate may be available for EP’s
clients at the hotel hosting the event. The reservation form will be sent to the client after the venue has been confirmed, but no later
than one month before the event begins.
3. Cancellation by client. The client has the right to cancel his/her participation in the event. Cancellation must be received by EP in
writing, either by mail, email or fax. If the client cancels with more than one month’s advance notice before the start of the event, EP
shall be entitled to retain and charge 50% of the total invoiced amount. If the client cancels with one month’s (or less) advance notice,
or fails to attend the event, then the client shall not be entitled to any refund nor any discount. Client’s failure to attend the event does
not cancel, decrease or in any matter waives the client’s obligation to fully pay the fee invoiced to the client by EP.
4. Cancellation by EP. While every reasonable effort is made to adhere to the advertised program, circumstances out of the control of
EP can arise, which may cause changes in the program, including but not limited to changes in the content, date(s), location or venue,
or special features of the planned event. Such circumstances include but are not limited to acts of terrorism, war, extreme weather
conditions, compliance with government requests, orders and legal requirements, failure of third party suppliers to timely deliver, and
failure to register the minimum targeted amount of attendees for a given event. EP reserves the right to change the content, date(s),
location or venue and/or special features of an event, to merge the event with another event, or to postpone it or cancel it entirely as
appropriate under the circumstances. Client agrees that EP shall not be liable for any cost, damage or expense which may be incurred
by client as a consequence of the event being changed, merged with another event, postponed or cancelled and client agrees to hold
EP harmless and to indemnify EP for any liability caused by any such changes, mergers, postponements or cancellations to the Client.
5. Cancellation of the event. In case EP cancels the event, EP may offer the client a full credit up to the amount actually paid by the
client to EP. This credit shall be valid for up to one year from the issue date of the invoice to attend any of EP’s events. The client shall
not be entitled to this credit as a contractual right.
6. Clients identification information. By signing of this sales contract and these terms and conditions the client gives full right to EP
to share the client’s identification information such as, but not limited to, client’s name, address, email addresses, phone numbers and
names of representatives with third parties, which participated on the same event as the client.
7. Governing law. This contract shall be governed and construed in accordance with the laws of the Slovak Republic (not including its
conflict of laws provisions). Any disputes arising out of this contract shall be brought before the courts of the Slovak Republic situated
in the city of Bratislava in the Slovak Republic.
8. Other currencies. In case that client requests payment in other than EP’s official currency (EUR), EP reserves the right to apply 8%
currency risk surcharge to the actual exchange rate.
Sales Contract
Please complete this form and send it back to:
E-mail to: killian.mabena@flemingeurope.com
or FAX: + 421 255 644 490
Client Identification Details
(Please complete form IN CAPITAL LETTERS for each client)
Ms Mrs Mr Surname:
Name:
Job Title:
Email:
Ms Mrs Mr Surname:
Name:
Job Title:
Email:
Ms Mrs Mr Surname:
Name:
Job Title:
Email:
Company/organisation Details
Name:
VAT Number:
(VAT No. for EU members / Tax Number for non-EU members)
Contact person:
Email:
Address:
City:
Country:
Phone:
Under European Union and Austrian tax regulations delegates are required to pay VAT in
any conference taking place in the Austria. Delegates may be entitled to reclaim this cost.
Payment Method
Please debit my
Visa Eurocard/Mastercard Diners club
Card Billing Address:
Street:
City:
Post/Zip Code
Card Holder´s Name:
Card Holder´s Signature:
Card Number:
Visa CVC Number or Eurocard/Mastercard CVV Number
(last 3 digits on the back of the card)
Valid from Expiry Date
I agree to Event Production s.r.o. debiting my card.
Authorization and Acceptance of
Sales contract Terms Conditions
I hereby declare I am authorised to sign this contract and terms
conditions in the name of the company/organisation:
Name:
Date:
Signature:
Booking is invalid without a signature
Conference Code: BALS167
Mlynské Nivy 71, 821 05 Bratislava, Slovakia
IČO: 44 59 74 52, IČ DPH: SK2022754448
1
Agreed Price of the service
18 € administration charge and 20% Austrian VAT will be applied
Payment is required within 5 working days
If you wish to pay in USD ($) or GBP (£) please contact us for more details.
In the name of Event Production s.r.o. I hereby declare Event Production s.r.o.
will adhere to this sales contract terms conditions
Eduard Vacula, Director
€ 1595Industry Professional